secwatch.observer — SEC 8-K summary
======================================

Issuer:     Odyssey Health, Inc. (ODYY)
CIK:        0001626644
Form:       8-K
Filed at:   2022-11-23T23:59:59+00:00
Accession:  0001683168-22-008028
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Odyssey Health receives $313,709 R&D rebate from Australian government for Phase I trial work
--------------------------------------------------------------------------------

- Rebate of $313,709 ($468,727 AUD) received on November 18, 2022.
- Funds are for clinical work conducted in Australia during fiscal year ended July 31, 2022.
- Rebate relates to the Company's Phase I human clinical trial expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822008028/0001683168-22-008028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822008028/odyssey_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-008028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer